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Abstract
Introduction: MicroRNAs (miRNAs) are being increasingly studied in relation to energy metabolism and body composition
homeostasis. Indeed, the quantitative analysis of miRNAs expression in different adiposity conditions may contribute to
understand the intimate mechanisms participating in body weight control and to find new biomarkers with diagnostic or
prognostic value in obesity management.
Objective: The aim of this study was the search for miRNAs in blood cells whose expression could be used as prognostic
biomarkers of weight loss.
Methods: Ten Caucasian obese women were selected among the participants in a weight-loss trial that consisted in
following an energy-restricted treatment. Weight loss was considered unsuccessful when ,5% of initial body weight (non-
responders) and successful when .5% (responders). At baseline, total miRNA isolated from peripheral blood mononuclear
cells (PBMC) was sequenced with SOLiD v4. The miRNA sequencing data were validated by RT-PCR.
Results: Differential baseline expression of several miRNAs was found between responders and non-responders. Two
miRNAs were up-regulated in the non-responder group (mir-935 and mir-4772) and three others were down-regulated (mir-
223, mir-224 and mir-376b). Both mir-935 and mir-4772 showed relevant associations with the magnitude of weight loss,
although the expression of other transcripts (mir-874, mir-199b, mir-766, mir-589 and mir-148b) also correlated with weight
loss.
Conclusions: This research addresses the use of high-throughput sequencing technologies in the search for miRNA
expression biomarkers in obesity, by determining the miRNA transcriptome of PBMC. Basal expression of different miRNAs,
particularly mir-935 and mir-4772, could be prognostic biomarkers and may forecast the response to a hypocaloric diet.
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Introduction
The discovery and characterization of small non-coding
molecules of RNA with approximately 20–30 nucleotides has
radically contributed to reinterpret the function of RNA and the
regulation of gene expression [1]. MicroRNAs (miRNAs) can
modulate (generally inhibiting) the expression of over one-third
of protein-coding genes by complementary binding to specific
nucleotide regions of mRNAs [2]. In this sense, in the version
19 of miRBase database (http://www.mirbase.org), 25,141
mature miRNAs have been identified in 193 species, and each
one can specifically target hundreds of genes (about 60% of
mammalian genes), being their dysregulation putatively involved
in the pathogenesis of many chronic diseases including cancer,
cardiovascular disease, type 2 diabetes and obesity [3].
Regarding obesity, miRNAs seem to participate in the
regulation of several important biological processes, such as
adipocyte differentiation, metabolic integration, fat metabolism
and insulin sensitivity [4]. Thus, different investigations have
compared the miRNA expression patterns between the undiffer-
entiated preadipocytes and the differentiated adipocytes, both in
3T3-L1 murine cells [5] and in human subcutaneous preadipo-
cytes [6]. These studies suggest that the miRNA expression
patterns play an important role in the regulation of cell
differentiation during the adipogenic process, accelerating or
inhibiting the process, and hence regulating fat cell development.
However, as occurs with many adipogenic genes whose expression
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increases during adipogenesis but decreases in adipocytes from ob/
ob and diet-induced obese mice [7], many miRNAs show inverse
regulatory patterns during adipogenesis and in obese patients [5].
These outcomes have been explained by the interference of
hypoxia, macrophage infiltration and proinflammatory cytokines
like TNF-a in the process [8]. Also, the miRNA expression
patterns of omental and subcutaneous adipose tissue show some
disparities that may contribute to intrinsic differences between
both depots and that eventually could influence the development
of some of the comorbidities associated to obesity [9].
The recent advances in sequencing and omics technologies have
enabled the characterization of all the miRNAs that are expressed
in a tissue or cell culture [10], allowing to identify new biomarkers
of diagnosis and prognosis, but also to search for novel gene
regulators for a number of chronic conditions, including obesity.
In this context, the search for obesity-related biomarkers or
prognostic markers of weight loss has been until now focused on
genetics (SNP identification) or transcriptomics (gene expression),
being whole blood or white cells the preferred biological sources
because of the less invasive method of extraction. Thus, several
SNPs have been identified in relation to the success of a weight loss
program [11], whereas mRNA microarrays have been also used to
early differentiate the populations of high and low responders to a
hypocaloric diet [12]. In relation to epigenetics, which usually
encompasses mitotically heritable but potentially reversible
changes in DNA methylation, histone modifications and miRNA
expression [13], most of the existing research has been focused on
DNA methylation, studying the differences between obese and
non-obese rodents [14–17] and humans [18,19], but also between
high and low responders to a low calorie diet [20–23] trying to
search for epigenetic biomarkers of response to the diet.
Concerning miRNAs, another epigenetic-related mechanism of
gene expression regulation that is influenced by dietary manipu-
lation [24], some studies have compared the expression differences
between obese and non-obese individuals in both mice [25–27]
and humans [6,28], demonstrating that some miRNAs are altered
in adipose tissue and circulation in obesity. Variations of miRNA
expression seem also to be involved in the severity and
susceptibility to nonalcoholic steatohepatitis (NASH) [29]. How-
ever, no studies have been focused on the early prediction of the
weight loss outcome after a dietary treatment, which can be of
great interest in the design of personalized nutrition.
The aim of the present research is to characterize the miRNA
expression pattern of subjects with a different outcome to a
hypocaloric dietary treatment by high-throughput sequencing in
peripheral blood mononuclear cells (PBMC), in order to find
prognostic biomarkers of response to the diet.
Subjects and Methods
Study Population and Ethics Statement
Ten Caucasian women with excess body weight
(BMI= 35.6 kg/m2) were selected among the participants in a
weight-loss trial that consisted in following an energy-restricted
treatment according to a food exchange system (8-week low-
calorie diet providing 800–880 kcal/day), as reported elsewhere
[20]. The diet supplied 15% of energy as proteins, 55% as
carbohydrates and 30% as fat [20]. After a detailed explanation
of the study, a written informed acceptance was obtained from
all participants in agreement with the Helsinki Declaration. This
consent document and the study protocol were previously
approved by the Ethical Committee of the Clı´nica Universidad
de Navarra (Ref.090/2008). At the baseline, a screening
including physical examination, medical history, activity patterns
and fasting blood profile was performed. Body weight was
recorded with a digital balance accurate to 0.1 kg (Seca 767,
Vogel & Halke, Hamburg, Germany), and height was measured
with a calibrated stadiometer (Seca 220, Vogel & Halke).
Measurements were carried out in underwear after an overnight
fast. Waist circumference was recorded at the midpoint between
the superior iliac crest and lower costal margin whereas hip
circumference was measured at the maximum protuberance of
the buttocks. Body mass index (BMI) was calculated as body
mass (kg) divided by height (m) squared. Total fat mass was
measured by bioelectrical impedance with a Quadscan 4000
equipment (Bodystat, UK). Baseline circulating glucose was
quantified by a specific colorimetric assay (Horiba ABX
Diagnostics, Montpellier, France) using an automatized system
(COBAS MIRA, Roche, Basel, Switzerland). Blood pressure was
recorded with a standard mercury sphygmomanometer (Minimus
II, Riester, Junginger, Germany) after at least 5 minutes of rest in
a sitting position, following standardized procedures according to
WHO criteria. Leisure time physical activity was estimated in
MET hours by a validated questionnaire [30], and the number
of hours devoted to different activities was multiplied by the
specific MET score of each activity.
Weight loss was considered unsuccessful when it was #5% of
initial body weight and successful when it was$5%. Based on this,
the sample was categorized as unsuccessful (n = 5) or successful
(n = 5) weight-loss subjects.
miRNA Sequencing by SOLiD v4
At baseline, PBMCs were isolated by differential centrifugation
using Polymorphprep (Axis Shield PoC AS, Oslo, Norway). The
PBMC band was harvested with a Pasteur pipette and, after
washing with phosphate-buffered saline (PBS), total RNA was
extracted by using a commercial kit (mirVana, Ambion, Austin,
TX, USA). RNA quality was assessed by measuring 1 ml of
100 ng/ml total RNA in a 2100 Bioanalyzer (Agilent Technolo-
gies, Palo Alto, CA, USA) by using a RNA 6000 Nano kit
(Agilent). The percentage of miRNAs (10–40 nucleotides) was
estimated with the same equipment by also analysing 1 ml total
RNA in a Small RNA Chip (Agilent). The small RNAs were
purified with the PureLink miRNA Isolation Kit (Invitrogen,
Carlsbad, CA, USA) and samples were concentrated with a speed
vacDNA. 3 ml (10 ng approximately) of miRNA were used for
next-generation sequencing. Quality of RNA was assessed by
260 nm absorbance with a Nanodrop ND-1000 spectrophotom-
eter (NanoDrop Technologies Inc, Wilmington, DE, USA), by
using Qubit fluorescence (Invitrogen), and by capillary electro-
phoresis with an Agilent 2100 Bioanalyzer (Agilent Technologies).
Fragment libraries compatible with the SOLiD platform were
obtained from small RNA by following the recommendations
provided by Life Technologies for SOLiDv4 sequencing (http://
www.umassmed.edu/uploadedFiles/nemo/STaR-smallRNAs-
QRC.PDF). The quality and quantity of the libraries were assessed
by Agilent 2100 Bioanalyzer and Qubit.
The equimolar mixture of the libraries was subjected to
emulsion PCR process for clonal amplification of the fragments,
followed by an enrichment process and chemical modification to
generate microspheres and allow loading in the reaction chamber,
as indicated by Life Technologies for SOLiD v4 sequencing. The
quality and quantity of the microspheres obtained from the pool of
libraries have been estimated taking into account the parameters
obtained from the workflow analysis. The reactions to obtain
sequences of 35 nucleotides +10 nucleotides have been subse-
quently carried out (Barcode in SOLiD v4). The quality of the
data obtained has been estimated using parameters provided by
miRNA High-Throughput Sequencing in Obesity
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the SETS software (SOLiD Experimental Tracking System). Mass
sequencing reactions of miRNAs and the bioinformatic analysis
were carried out by Sistemas Geno´micos (Spain) [http://www.
sistemasgenomicos.com] and the results are shown as a supple-
mentary table (table S1).
Reads were mapped against the latest version of the human
genome (version GRch37/hg19) using the BWA software [31].
Known miRNAs were identified and quantified using BedTools
[32] and miRBase (v17). Novel miRNAs were discovered by
secondary structure predictions with the mirDeep2 package [33].
Reverse-Transcription and Quantitative Real-time PCR
(qRT-PCR) of miRNAs
Total RNA (3 ng) was reverse-transcribed using the TaqManH
MicroRNA Reverse Transcription kit (Applied Biosystems, Foster
City, CA, USA) and the miRNA-specific reverse-transcription
primers provided with the TaqManH MicroRNA Assay (Applied
Biosystems, Foster City, CA, USA). For the reverse transcription
iCyclerTM Thermal cycler (Applied Biosystems, Foster City, CA,
USA) was used with the following conditions: 16uC for 30 min;
42uC for 30 min and 85uC for 5 min. 1.33 ml of miRNA-specific
cDNA from this reaction was amplified with the TaqMan
Universal PCR master mix and the respective specific probe
provided in the TaqManH MicroRNA Assay (Applied Biosystems,
Foster City, CA, USA). The targeted miRNA assay sequences
were as follows: miR-27b 59-UUCACAGUGGCUAAGUU-
CUGC-39, miR-223’- 59UGUCAGUUUGUCAAAUACCCCA-
39, miR-224 59-CAAGUCACUAGUGGUUCCGUU-39, miR-
4772-3p 59-CCUGCAACUUUGCCUGAUCAGA-39, and miR-
935 59-CCAGUUACCGCUUCCGCUACCGC-39. PCR was
performed in an iCyclerTM–MyiQTM Real-time PCR Detection
System (Applied Biosystems, Foster City, CA, USA). Amplification
was performed at 95uC for 10 min, followed by 40 cycles of 95uC
for 15 s and 60uC for 1 min. miRNA-148a (sequence 59-
UCAGUGCACUACAGAACUUUGU-39), a miRNA with a fold
change close to 1 in mass sequencing, was used as an endogenous
control. All mRNA levels were normalized to the values of
miRNA-148a and the results expressed as fold changes of
threshold cycle (Ct) value relative to controls using the 22DDCt
method [34].
Statistical Analyses
The Mann-Whitney U test was used to analyse differences
between both responder and non-responder groups regarding
anthropometric and biochemical variables. For this purpose, SPSS
15.0 software (SPSS, Chicago, IL) was used. SPSS was also used to
perform bivariate correlations and calculate Pearson’s r.
Statistical analyses of high-throughput sequencing results were
performed with the DESeq software [35] comparing the
expression of each miRNA in the responder and non-responder
subjects. An adjusted value of probability was achieved by using
the Benjamini-Hochberg method for False Discovery Rate (FDR)
correction. In the results section, differences in miRNA expression
with an adjusted P-value,0.05 were interpreted as significant,
whereas those with adjusted P-value,0.10 were considered as
trends towards significance.
Those miRNAs with a significant fold change of 2 or greater (in
terms of absolute value) were mapped by chromosome. Moreover,
chromosome X and 14 were clustered based on inter-miRNA
distance ,100000 (http://mirbase.org) [36]. These results are
shown in tables S2 and S3.
Prediction of targets for those miRNAs that showed significant
differential expression between responders and non-responders
was undertaken by means of two widely used algorithms: miRanda
and TargetScan. The software MicroCosm Targets Version 5 [36]
and the prediction source http://microRNA.org [37] were used
for calculating miRanda algorithm, and the software TargetScan-
Human 6.0 in the case of TargetScan algorithm [38]. At the time
of writing, miR-4772 was not in the MicroCosm Targets Version 5
and TargetScanHuman 6.0 databases.
Results
Body Weight after Hypocaloric Diet Treatment
A statistically higher body weight reduction in the responder
group (subjects who lost $5% body weight) was observed when
compared to the non-responders (subjects who lost #5% body
weight), being the physical activity pattern similar between both
groups (table 1).
miRNA Expression Profile in PBMC Cells
Two miRNAs were up-regulated in the non-responder group
according to high-throughput sequencing at baseline (figures 1 and
2): mir-935, with a fold change of 7.1 (adjusted P -value of 0.008
and a fold change value obtained by qRT-PCR of 9.05, P=0.02),
and mir-4772, with a fold change of 5.3 (adjusted P-value of 0.022
and a fold change value obtained by qRT-PCR of 4.29, P=0.09).
Three other miRNAs were down-regulated but showed an
adjusted P-value lower than 0.1 and a fold change higher than
two or lower than minus two (figures 1 and 2): mir-223, with a fold
change of 2.5 (the fold change value obtained by qRT-PCR was
2.72, P=0.03); mir-224, with a fold change of 24.1 (the fold
change value obtained by qRT-PCR was 22.33, P=0.08); and
mir-376b, with a fold change of 24.2.
Six other transcripts are shown in table 2 because, according to
high-throughput sequencing, they presented differential expression
between responders and non-responders before using the Benja-
mini-Hochberg correction for multiple tests (P-value,0.005 and
fold change of 2.9 or greater in terms of absolute value, but an
adjusted P-value higher than 0.1). Two of them were overex-
pressed, being mir-183 the most up-regulated with a fold change of
9.0. Other four miRNAs were down-regulated, showing mir-433 a
fold change of 29.6 and mir-27b a fold change of 23.41 (the fold
change value obtained by qRT-PCR for mir-27b was 21.54,
P=0.09; figure 2).
Table S4 shows the most expressed miRNAs in PBMC cells
based on read counts. The transcript mir-223, which was
differentially expressed when comparing responder and non-
responder subjects, is the most abundant in this type of cells,
followed by mir-150 and mir-126.
Novel miRNAs
From a total of 102 detected miRNAs with a significant fold
change of 22 or greater, fourteen not identified miRNAs
(according to miRBase database) were found. Although none of
these novel miRNAs showed significant differences between
responders and non-responders (table S5), and despite their
relatively low expression levels, they deserve a study in the
future.
Prediction of Targets for miRNAs
The predicted gene targets for miRNAs were carried out for
miR-935, miR-223, miR-224, miR-376b, miR-542, miR-433,
miR-154 miR-27b, miR-409, miR-183, miR-542-3p and miR-
4772-3p with miRanda and TargetScan algorithms. With the
exception of miR-542, predicted targets related to obesity and its
co-morbidities were found in these miRNAs (table 3). In the table
S6, the list of target mRNAs of each differentially expressed
miRNA High-Throughput Sequencing in Obesity
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miRNA has been expanded, including the most relevant obesity-
related genes putatively regulated by each miRNA.
Chromosomal Localization of miRNAs
Sequenced miRNAs with a significant fold change of 2 or
greater (in absolute values) have been mapped by chromosome
and shown as supplementary data (tables S2 and S3) accompanied
by the differences between responders and non-responders. Most
of the miRNAs, as determined by the total number of reads
mapped per chromosome, are located in the chromosomes 14 and
X. When the miRNAs were clustered based on chromosome
location and, in the case of chromosomes X and 14, on inter-
miRNA distance ,100000 (according to miRBase), three clusters
located in chromosomes 9, X and 18 were significantly up-
regulated. Another three clusters were significantly down-regulat-
ed, two of them in chromosome X and one in chromosome 7.
Associations/correlations between miRNAs and
Anthropometric Measurements or Indexes
Both mir-935 and mir-4772 showed close associations with the
magnitude of weight loss (figure 3a, with Pearson correlation
coefficients of 0.721 and 0.770, respectively). Interestingly, similar
results were observed with other miRNAs presenting low P-values
in the non-adjusted test, such as mir-874 (P=0.014), mir-199b
(P=0.020), mir-766 (P=0. 052), mir-589 (P=0.076), and mir-
148b (P=0.389). Other miRNAs differentially expressed between
responders and non-responders shown in figure 1, as is the case of
mir-223 and mir-224, evidenced a trend towards significance in
their correlation with the magnitude of weight loss (Pearson
correlation coefficients of 0.597 and 0.599 and P-values of 0.069
and 0.067, respectively).
There were no baseline differences between the participants in
the study regarding their anthropometric and biochemical
Table 1. Characteristics of the population at baseline and after the 8-week intervention categorized according to the outcome
(responders and non-responders to the energy restriction).
NON RESPONDERS (n=5) RESPONDERS (n =5) P-value
Age (years) 4262 3862 0.31
Initial Body Weight (kg) 90.366.2 95.863.9 0.55
Initial Body Mass Index (BMI) 34.862.1 36.461.7 0.69
Initial % Fat (Impedance) 46.262.1 46.961.5 1.00
Waist Circumference (cm) 10565 10764 0.84
Hip Circumference (cm) 12065 12564 0.58
Waist/Hip ratio 0.8860.04 0.8660.01 0.69
Physical activity (MET h/week) 12.667.5 12.168.4 0.85
Fasting Glucose (mmol/L) 4.9460.21 4.5660.27 0.31
Systolic Blood Pressure (mm Hg) 12265 12364 1.00
Diastolic Blood Pressure (mm Hg) 7064 6262 0.15
Weight Loss (kg) 3.160.7 10.860.6 0.008
Comparisons between groups were made using Mann-Whitney U test. Values represent mean 6 SEM.
doi:10.1371/journal.pone.0054319.t001
Figure 1. miRNAs differentially expressed between responders and non-responders at baseline (adjusted P-value,0.1). The data
correspond to the mean of the transcripts sequenced in each group 6 SEM.
doi:10.1371/journal.pone.0054319.g001
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measurements (table 1). However, we wanted to know if the
expression of some miRNAs in PBMCs were associated with initial
BMI, the most used parameter of adiposity (figure 3b). Moderate
associations were found between the expression of some miRNAs
and this phenotypic marker of adiposity, with mir-3615 and mir-
33b being the more relevant. These miRNAs associated to initial
body weight could be candidates for being implicated in obesity
onset and complications, although it should be elucidated in later
studies.
It is noteworthy that the expression of some of the analysed
miRNAs was highly correlated among them, as observed when
comparing the miRNAs that were more associated with weight loss,
such asmir-935, mir-4772, mir-223, mir-409 andmir-27b (figure 4).
Discussion
The current research is pioneer in the use of high-throughput
sequencing in the search for expression biomarkers in obesity, by
determining the whole miRNA transcriptome in human PBMCs.
The current article employed a similar approach that Ahn et al.
[39] when determined the miRNA transcriptome in the newborn
mouse ovaries. In our case, we studied the miRNA transcriptome
in peripheral blood cells of ten obese women that followed a
weight-loss program, with 5 of them categorized as high
responders and the other 5 as non-responders, according to
Campion et al. [40]. This kind of cells has been selected because
they are widely and successfully used in the search for non-invasive
biomarkers as surrogates of tissues that are not easily accessible,
such as adipose tissue [41]. We found 5 miRNAs whose expression
was different at baseline between both groups (with an adjusted p-
value lower than 0.1). Among them, only mir-223 (fold change of
2.5) and mir-224 (fold change of24.1) had been previously related
to obesity. Thus, mir-223 has been reported to regulate the
expression of many genes, as for example GLUT4 [42], and is
overexpressed in epididymal adipocytes of obese mice [43] and
down-regulated in plasma of diabetic patients [40]. On the other
Figure 2. Comparison between the two technologies applied in this work, high-throughput sequencing (dark columns) and RT-PCR
(light columns). The expression of mir-27b, mir-223, mir-224, mir-935 and mir-4772-3p is represented as fold change of non-responders with
respect to responders at baseline. The data correspond to the mean 6 SEM. Comparisons between groups were made using adjusted P-value (mass
sequencing) and Mann-Whitney U test (RT-PCR). *, p,0.05; t, p,0.1.
doi:10.1371/journal.pone.0054319.g002
Table 2. miRNA transcripts showing differential miRNA expression between responders and non-responders by using the mass
sequencing approach (non-adjusted P-value,0.005 and fold change.2.9), but whose adjusted P-values were not significant.
miRNAs Responders Non-responders Fold Change Non-adjusted P-value
mir-183 464 36613 8.96 0.004
mir-542 148624 5556158 3.75 0.003
mir-433 61616 666 29.56 0.003
mir-154 2696105 79637 23.42 0.005
mir-27b 16556550 4856217 23.41 0.003
mir-409 474461184 16096722 22.95 0.005
The data report the mean of the number of transcripts sequenced in each group 6 SEM.
doi:10.1371/journal.pone.0054319.t002
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hand, mir-224 is the only differentially expressed miRNA that has
been previously related to adiposity, being up-regulated in 3T3-L1
mature adipocytes 9 days post induction when compared with
preadipocytes [44].
Regarding the expression of the other 3 miRNAs shown in
figure 1 (mir-935, mir-4772 and mir-376b), this study is apparently
the first that finds differences in PBMC cells and that relates their
expression with the susceptibility to lose weight. More studies
Table 3. Short selection of target mRNAs of the microRNAs with differences in expression between responders and non-
responders to the energy-restricted.
miRNA Sequence miRanda algorithm
TargetScan
algorithm
(source mirbase.org ) MicroCosm microRNA TargetScan
hsa-mir-935 GGCGGGGGCGCGGGCGGCAGUGGCGGGAGCGGCCCCU
CGGCCAUCCUCCGUCUGCCCAGUUACCGCUUCC
GCUACCGCCGCCGCUCCCGCU
HDAC1, ADRA1A, LPL, RBP5 HIF1A ADRB1
hsa-mir-223 CCUGGCCUCCUGCAGUGCCACGCUCCGUGUA
UUUGACAAGCUGAGUUGGACACUCCAUGU
GGUAGAGUGUCAGUUUGUCAAAUACCCCAA
GUGCGGCACAUGCUUACCAG
IGFL2c, DNMT1, HDAC2,
HDAC8, SIRT5
LIPG IGF1R, HDAC4
hsa-mir-224 GGGCUUUCAAGUCACUAGUGGUUCCG
UUUAGUAGAUGAUUGUGCAUUGUUUCA
AAAUGGUGCCCUAGUGACUACAAAGCCC
MC3R, SREBF1 ACAT1 IRS2
hsa-mir-376b CAGUCCUUCUUUGGUAUUUAAAACGU
GGAUAUUCCUUCUAUGUUUACGUGA
UUCCUGGUUAAUCAUAGAGGAAAAUCCA
UGUUUUCAGUAUCAAAUGCUG
FABP4, CPT2 LIPH, PPARG, G6PC2,
HDAC9, NR3C1
HDAC9, IGF1R
hsa-mir-433 CCGGGGAGAAGUACGGUGAGCCUGUCAUUAUU
CAGAGAGGCUAGAUCCUCUGUGUUGAGAAG
GAUCAUGAUGGGCUCCUCGGUGUUCUCCAGG
HDAC6, ADRA1A, IGFBP1,
ACOX2, LPL, LIPE
GCLC, FRZB, ADRA1A, LEPR
has-mir-154 GUGGUACUUGAAGAUAGGUUAUCCGUGU
UGCCUUCGCUUUAUUUGUGACGAAUCAUA
CACGGUUGACCUAUUUUUCAGUACCAA
ADRA1A, IGF1
hsa-mir-27b ACCUCUCUAACAAGGUGCAGAGCUUAGCU
GAUUGGUGAACAGUGAUUGGUUUCCGCUU
UGUUCACAGUGGCUAAGUUCUGCACCUG
AAGAGAAGGUG
PPARG, INSR, MC4R, SIRT5 SCD5, ACAT1, PPARG, INSR, IRS1,
CNR1, PPARGC1B,
IGF1
hsa-mir-409 UGGUACUCGGGGAGAGGUUACCCGAG
CAACUUUGCAUCUGGACGACGAAUGUUG
CUCGGUGAACCCCUUUUCGGUAUCA
FZD3, PPARGC1A,
APOF, AGPAT9
has-mir-183 CCGCAGAGUGUGACUCCUGUUCUGUGUA
UGGCACUGGUAGAAUUCACUGUGAACA
GUCUCAGUCAGUGAAUUACCGAAGGG
CCAUAAACAGAGCAGAGACAGAUCCACGA
HDAC10, HDAC8, HDAC6,
CRTC2, DGKH, GK5, PLB1,
CPT2
ACAD8 PEX19
hsa-mir-542-3p UGUGACAGAUUGAUAACUGAAA IGFBP1, IGFBP6, FABP3,
PLA2G4B, LIPA, APOL5,
ELOVL3, SLC27A3, PPARD, TNF
FABP3 GDPD4, PLA2R1,
hsa-mir-4772-3p CCUGCAACUUUGCCUGAUCAGA ACSL1, PDK3,
PPARGC1A,
ERLIN2, IGF2BP1,
IGF2, LRP8,
CREBBP
ACAD: acyl-CoA dehydrogenase family; ACAT: acetyl-coa acetyltransferase; ACOX: acyl-coenzyme A oxidase, peroxisomal; ACSL: acyl-CoA synthetase long-chain family
member; ADRA1A: alpha-1A adrenergic receptor; ADRB1: beta-1 adrenergic receptor; AGPAT: 1-acylglycerol-3-phosphate o-acyltransferase; APO: apolipoprotein;
CREBBP: CREB binding proteı´na; CNR: cannabinoid receptor; CPT: Carnitine O-palmitoyltransferase, mitochondrial precursor; CRTC: transducer of regulated cAMP
response element-binding protein (CREB); DGKH : diacylglycerol kinase eta; DNMT: DNA (cytosine-5)-methyltransferase; ELOVL: elongation of very long chain fatty acids
protein; ERLIN: ER lipid raft associated; FABP: fatty acid-binding protein, adipocyte; FRZB: frizzled-related protein; FZD: frizzled, drosophila, homolog of; GCLC: glutamate-
cysteine ligase, catalytic subunit; GDPD: glycerophosphodiester phosphodiesterase domain containing; GIPR: gastric inhibitory polypeptide receptor; GK: glycerol
kinase; G6PC: glucose-6-phosphatase, catalytic; HDAC: histone deacetylase; HIF1A: hypoxia-inducible factor; IGF1: insulin-like growth factor 1; IGF1R: insulin-like growth
factor 1 receptor; IGFBP: insulin-like growth factor-binding protein precursor; IGFL2c: insulin growth factor-like family member 2 precursor; INSR: insulin receptor; IRS:
insulin receptor substrate; LEPR: leptin receptor; LIPA: lysosomal acid lipase/cholesteryl ester hydrolase precursor; LIPE: hormone-sensitive lipase; LIPG: factor 1, alpha
subunit; lipase, endothelial; LIPH: lipase h; LRP: Low density lipoprotein receptor-related protein, apolipoprotein e receptor;LPL: Lipoprotein lipase precursor; MCR:
Melanocortin receptor; NR3C1: glucocorticoid receptor; PDK: pyruvate dehydrogenase kinase, isozyme; PEX: peroxisomal biogenesis factor; PLA2G4B: cytosolic
phospholipase A2 beta; PLA2R1: phospholipase A2 receptor 1; PLB: phospholipase B; PPARD: Peroxisome proliferator-activated receptor delta; PPARG: Peroxisome
proliferator-activated receptor gamma; PPARGC: peroxisome proliferator-activated receptor gamma, coactivator; RBP: retinol-binding protein, cellular; SLC27A: long-
chain fatty acid transport protein; SCD: stearoyl-coa desaturase; SIRT5: NAD-dependent deacetylase sirtuin-5; SREBF1: sterol regulatory element-binding protein 1; TNF:
tumor necrosis factor precursor.
doi:10.1371/journal.pone.0054319.t003
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(in vitro and in animals) are necessary to confirm a role of these 3
transcripts in obesity and energy metabolism.
Some of the miRNAs reported in table 2 have been previously
associated with different diseases, especially cancer. Among them,
there are three miRNAs (mir-183, mir-433 and mir-27b) that seem
to play an important role in the regulation of gene expression in
metabolic disorders. Thus, regarding mir-183 (fold change of 9.0),
the incubation of 3T3-L1 adipocytes with insulin inhibits its
expression [45]. mir-433 (fold change of 29,6) is activated by the
estrogen receptor ESRRG, in which several SNPs have been
associated with higher risk of type 2 diabetes by GWAS [46] and
that acts as a co-activator of the demethylating enzyme Dnmt1
[47]. Although most articles studying this specific miRNA are
focused on cancer [48], it is also differentially expressed in liver of
patients with non-alcoholic fatty liver disease [49]. Finally, mir-
27b (fold change of 23,4), which is an oxidative stress-responsive
miRNA that suppresses lipopolysaccharide-induced activation of
NFkB [50], is up-regulated in epididymal adipocytes of obese mice
[43] and impairs human adipocyte differentiation by targeting
PPARc [51].
The moderate correlations observed between the expression of
the different miRNAs in PBMCs and the BMI at baseline
(figure 3b) suggest that small differences in adiposity do not
appears to strongly affect miRNA expression in this kind of cells.
However, the magnitude of weight loss strongly correlated with the
expression of several miRNAs at baseline (figure 3a), suggesting a
role of these miRNAs in body weight regulation, energy
homeostasis and response to the diet. The significant correlations
found between the expression of different miRNAs (figure 4)
suggest that, at least in PBMCs, their expression could be
regulated by common factors and even that they might share
similar regulatory functions.
Some of the potential targets of the miRNAs identified in the
present study are represented in table 3. Those that have been
Figure 3. a. Associations between the expression of some miRNAs and body weight change during the energy restriction period.
miRNA expression as number of transcripts sequenced. Pearson product-moment correlation coefficient has been applied. b. Associations between
the expression of some miRNAs and the baseline body mass index (BMI) of the subjects. miRNA expression as number of transcripts sequenced.
Pearson product-moment correlation coefficient has been applied.
doi:10.1371/journal.pone.0054319.g003
Figure 4. Associations between the expression of different miRNAs that are involved in the response to the dietary treatment. Data
represent the number of transcripts sequenced. Pearson product-moment correlation coefficient has been applied.
doi:10.1371/journal.pone.0054319.g004
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extensively related to obesity, energy homeostasis and insulin
signalling, as well as those that can act at an epigenetic level, have
been reflected in the table. This is the case of genes like
peroxisome proliferator-activated receptor gamma (PPARG),
glucocorticoid receptor (NR3C1), hypoxia-inducible factor 1,
alpha subunit (HIF1A), gastric inhibitory polypeptide receptor
(GIPR), histone deacetylases (HDAC) and methyltransferases
(DNMT). None of the miRNAs shown in table 3 have been
previously studied in relation to the expression of these genes in
models of obesity or weight regulation. So that, in vitro studies with
siRNAs or addition of miRNAs to the culture medium of 3T3-L1
cells, primary adipocytes, monocytes, macrophages or other key
cell types in the development of obesity, are needed to elucidate
the real importance of these miRNAs on the regulation of the
expression of these genes. However, previous studies have revealed
an interaction between some miRNAs, none of them differentially
expressed in our study, and the expression of HIF1A (miR-210
[52] and miR-101 [53], among many others), PPARG (such as
miR-130 [54]), or NR3C1 (including miR-18 and 124a, [55]),
suggesting that miRNAs may play an important role in the
regulation of these genes and the related pathways. It is
noteworthy that some of the analyzed miRNAs have histone
deacetylases and methyltransferases as predicted targets, suggest-
ing an epigenetic loop between miRNAs and histone modifications
in gene expression regulation.
Some of the highly abundant miRNA transcripts observed in
the present study coincide with those reported by Vaz et al. [10] in
a previous analysis of microRNA transcriptome in PBMCs by
deep sequencing, as for example mir-29a, mir-21, mir-191 or let-
7g. However, the disparities could be partially attributed to the
difference in technology (SOLiD v4 versus SOLEXA).
This is the first work that determines the whole miRNA
transcriptome by using high-throughput sequencing in the search
for biomarkers related to obesity and body weight regulation. The
results of this study stress the importance of miRNA expression in
blood cells as biomarkers of weight loss and response to the diet
(prognostic biomarkers), which could be used in the design of
personalized nutrition. Also, they suggest that the expression of
different miRNAs in blood cells might be implicated in the
regulation of energy homeostasis and body weight. However, it
should be emphasized that some of the miRNA expression
differences observed between responders and non-responders
could be due to (or influenced by) the diet at baseline or other
factors, such as physical activity, genetic background, dietary
habits or immune function, that should be analyzed in further
studies.
To conclude, the present study proposes the basal expression
levels of different miRNAs in blood cells, particularly mir-935,
mir-4772, mir-223, mir-224 and mir-376b, as prognostic bio-
markers of response to the diet. This research represents a
milestone in the design of personalized nutrition by taking into
account miRNA expression in blood cells, and opens the door to
the study of different miRNAs as novel biomarkers of weight loss.
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